New insights for infection mechanism and potential targets of COVID-19: Three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches
- PMID: 37220535
- PMCID: PMC9993661
- DOI: 10.1016/j.chmed.2022.06.014
New insights for infection mechanism and potential targets of COVID-19: Three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches
Abstract
The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with high pathogenicity and infectiousness has become a sudden and lethal pandemic worldwide. Currently, there is no accepted specific drug for COVID-19 treatment. Therefore, it is extremely urgent to clarify the pathogenic mechanism and develop effective therapies for patients with COVID-19. According to several reliable reports from China, traditional Chinese medicine (TCM), especially for three Chinese patent medicines and three Chinese medicine formulas, has been demonstrated to effectively alleviate the symptoms of COVID-19 either used alone or in combination with Western medicines. In this review, we systematically summarized and analyzed the pathogenesis of COVID-19, the detailed clinical practice, active ingredients investigation, network pharmacology prediction and underlying mechanism verification of three Chinese patent medicines and three Chinese medicine formulas in the COVID-19 combat. Additionally, we summarized some promising and high-frequency drugs of these prescriptions and discussed their regulatory mechanism, which provides guidance for the development of new drugs against COVID-19. Collectively, by addressing critical challenges, for example, unclear targets and complicated active ingredients of these medicines and formulas, we believe that TCM will represent promising and efficient strategies for curing COVID-19 and related pandemics.
Keywords: COVID-19; Huashi Baidu Formula; Jinhua Qinggan Granules; Lianhua Qingwen Capsule; Qingfei Paidu Decoction; SARS-CoV-2; Xuanfei Baidu Formula; Xuebijing Injection; traditional Chinese medicine.
© 2022 Tianjin Press of Chinese Herbal Medicines. Published by ELSEVIER B.V.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
Similar articles
-
Traditional Chinese medicine for treatment of novel infectious diseases: Current status and dilemma.Biosci Trends. 2021 Sep 22;15(4):201-204. doi: 10.5582/bst.2021.01263. Epub 2021 Jul 1. Biosci Trends. 2021. PMID: 34193750
-
Traditional Chinese medicine to treat COVID-19: the importance of evidence-based research.Drug Discov Ther. 2020;14(3):149-150. doi: 10.5582/ddt.2020.03054. Drug Discov Ther. 2020. PMID: 32669523
-
Potential herb‒drug interactions between anti-COVID-19 drugs and traditional Chinese medicine.Acta Pharm Sin B. 2023 Jun 5;13(9):3598-637. doi: 10.1016/j.apsb.2023.06.001. Online ahead of print. Acta Pharm Sin B. 2023. PMID: 37360014 Free PMC article. Review.
-
Composition, Clinical Efficiency, and Mechanism of NHC-Approved "Three Chinese Medicines and Three Chinese Recipes" for COVID-19 Treatment.Front Pharmacol. 2022 Feb 4;12:781090. doi: 10.3389/fphar.2021.781090. eCollection 2021. Front Pharmacol. 2022. PMID: 35185537 Free PMC article. Review.
-
Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6.Biosci Rep. 2021 Jan 29;41(1):BSR20202583. doi: 10.1042/BSR20202583. Biosci Rep. 2021. PMID: 33146673 Free PMC article.
Cited by
-
Unravelling the mechanism of action of Huashibaidu formula volatile metabolome for the treatment of COVID-19 and its mutants from the perspectives of network pharmacology and molecular docking.Medicine (Baltimore). 2025 May 30;104(22):e42669. doi: 10.1097/MD.0000000000042669. Medicine (Baltimore). 2025. PMID: 40441210 Free PMC article.
-
A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization.Chin Med. 2025 Mar 24;20(1):40. doi: 10.1186/s13020-025-01075-4. Chin Med. 2025. PMID: 40122800 Free PMC article. Review.
-
Metabolomic characteristics and related pathways in patients with different severity of COVID-19: a systematic review and meta-analysis.J Glob Health. 2025 Feb 28;15:04056. doi: 10.7189/jogh.15.04056. J Glob Health. 2025. PMID: 40019163 Free PMC article.
-
Current landscape of innovative drug development and regulatory support in China.Signal Transduct Target Ther. 2025 Jul 22;10(1):220. doi: 10.1038/s41392-025-02267-y. Signal Transduct Target Ther. 2025. PMID: 40691459 Free PMC article. Review.
-
Anemoside B4 inhibits SARS-CoV-2 replication in vitro and in vivo.Chin Herb Med. 2023 Dec 13;16(1):106-112. doi: 10.1016/j.chmed.2023.09.005. eCollection 2024 Jan. Chin Herb Med. 2023. PMID: 38375049 Free PMC article.
References
-
- Báez-Santos Y.M., Barraza S.J., Wilson M.W., Agius M.P., Mielech A.M., Davis N.M.…Mesecar A.D. X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases. Journal of Medical Chemistry. 2014;57(6):2393–2412. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous